A new systematic review and meta-analysis published July 15, 2026 in eClinical Medicine indicates that GLP-1 receptor agonists (GLP-1RAs) — drugs developed for type 2 diabetes and weight loss (examples include liraglutide, semaglutide, dulaglutide and tirzepatide) — may reduce key symptoms of binge eating in people living with overweight or obesity.
What the researchers did
Investigators searched major medical databases for randomized controlled trials (RCTs) published from 2005 through April 2026 that compared any GLP-1RA with placebo or another active treatment and reported validated measures of binge eating or related eating behaviors (loss-of-control eating, disinhibited eating, emotional eating, and cognitive/dietary restraint). Trials enrolling people with severe concurrent illnesses were excluded. In total, 25 RCTs met inclusion criteria, enrolling 8,069 participants (about two-thirds female, majority identifying as White), with a median age of 47. Most participants were living with overweight or obesity; only three trials specifically recruited people diagnosed with binge eating disorder (BED). Study durations ranged from 6 to 104 weeks.
Main findings
– Moderate, consistent reductions in core binge eating symptoms were observed among participants treated with GLP-1RAs versus controls. Effect sizes indicate small-to-moderate improvements across studies.
– Loss of control eating — a central feature of binge episodes — declined, suggesting participants reported fewer episodes of feeling unable to stop or control eating.
– Emotional eating (eating in response to negative emotions) was also moderately reduced.
– GLP-1RA treatment was associated with increased cognitive or dietary restraint, meaning people reported a greater conscious effort to limit food intake.
Interpretation and limitations
The results suggest GLP-1RAs could be a promising adjunctive option to help reduce binge-related behaviors in people with overweight or obesity. However, the body of evidence has important limitations: most trials did not specifically enroll people diagnosed with BED, many included populations without formal eating disorder diagnoses, and all included studies had either some concerns or a high risk of bias (for example, missing data or possible unblinding). That means findings should be interpreted cautiously and may not generalize to everyone with BED.
Clinical cautions
Experts emphasize that GLP-1RAs should not replace established, evidence-based treatments for binge eating disorder such as cognitive behavioral therapy (CBT). Clinicians and patients should consider the following:
– An eating disorder specialist should be consulted before starting a GLP-1RA if BED or other eating disorders are suspected, because non-specialists may not screen for these conditions and rapid weight loss or increased dietary restriction could, in some cases, worsen disordered eating.
– Increased cognitive restraint reported with GLP-1RA use may reflect healthier self-regulation for some people, but in others it could signal problematic restriction linked to disordered behaviors.
– Long-term effects of GLP-1RAs on eating disorder symptoms and recovery remain uncertain.
What’s needed next
Researchers call for longer-term RCTs that specifically recruit people with binge eating disorder, include diverse participant samples, and monitor both eating-disorder symptoms and nutritional/psychological outcomes. Until more targeted evidence is available, GLP-1RAs may be considered as part of a broader, individualized treatment plan — ideally coordinated with eating disorder treatment professionals — rather than a stand-alone cure.
Bottom line
GLP-1 receptor agonists appear to reduce binge eating severity, loss of control eating, and emotional eating in people with overweight or obesity in randomized trials, but evidence is limited by trial populations and risk of bias. They may serve as useful adjuncts to psychotherapy for some patients, but anyone with suspected or diagnosed BED should consult an eating disorder specialist before starting these medications, and more research is needed to establish long-term safety and effectiveness.
